Construction on Track for Eli Lilly's State-of-the-Art Pharmaceutical Facility in Alzey, Germany
Pharmaceutical building construction at Eli Lilly's Alzey location proceeding as planned. - Construction progress remains on track for Eli Lilly's pharmaceutical site in Alzey.
Eli Lilly, a leading player in the pharma industry, is gearing up to open its cutting-edge medicine manufacturing facility in Alzey, Germany, by the end of 2027. The construction of this 260-meter-long complex, encompassing offices, labs, production, and storage areas, is currently bang on schedule, as confirmed by CEO Dave Ricks during a site visit. He praised the swift decision-making processes that led to the implementation of this billion-euro project in Rhineland-Pfalz.
Eli Lilly's substantial investment of approximately 2.3 billion euros in this Alzey-based production site for injectable medications includes the diabetes drug Mounjaro, featuring the active ingredient Tirzepatid. The same active ingredient is also present in Eli Lilly's weight loss medication Zepbound.
Ricks reported in 2020 that this ambitious global production expansion, inclusive of a $50 billion budget worldwide, included the high-tech production site in Alzey. He added that this Alzey facility would significantly enhance Lilly's capacity to deliver innovative, high-quality medicines that patients rely on.
The billion-euro investment is estimated to create around 1,000 jobs in Alzey. Minister-President Alexander Schweitzer (SPD) hailed this as a massive gain and a tremendous opportunity for Rhineland-Pfalz's budding biotechnology sector.
- Alzey
- Pharma
- Eli Lilly
- Production site
- Schedule
- Rhineland-Pfalz
- Billion-euro project
This project is a crucial component of Eli Lilly's global expansion plan and represents an investment of around $2.5 billion (a billion euros). The new facility in Alzey is designed to incorporate next-generation manufacturing technologies and will be one of Lilly's most technologically advanced sites.
Additional Insights:
- As of May 2025, construction on the new facility is progressing actively.
- The Alzey site is part of Lilly's broader $55 billion global capital expansion commitment since 2020, which includes sites in the US and Europe (Italy, France, Ireland, and Germany).
- The Alzey facility, with its focus on advanced pharmaceutical manufacturing capabilities, is set to become a cornerstone of Lilly's European manufacturing infrastructure.
- Eli Lilly's multibillion-dollar investment in the Alzey production site, estimated to be around $2.5 billion (a billion euros), is a significant addition to its global expansion plan, featuring next-generation manufacturing technologies.
- The implementation of this billion-euro project in Rhineland-Pfalz by Eli Lilly, including the diabetes drug Mounjaro and weight loss medication Zepbound, is creating over a thousand job opportunities in Alzey, bolstering the region's growing biotechnology sector.
- Apart from the Alzey facility, other sites in the US and Europe (Italy, France, Ireland, and Germany) also form part of Eli Lilly's broader $55 billion global capital expansion commitment since 2020, positioning advanced pharmaceutical manufacturing capabilities at the core of its European manufacturing infrastructure.
